Home Newsfeeds BTIG Downgrades T2 Biosystems to Neutral

BTIG Downgrades T2 Biosystems to Neutral

BTIG analyst Mark Massaro downgrades T2 Biosystems (NASDAQ:TTOO) from Buy to Neutral.

byBenzinga Newsdesk

July 7, 2022

1 minute read

BTIG analyst Mark Massaro downgrades T2 Biosystems (NASDAQ:TTOO) from Buy to Neutral.

Apple Q2 Earnings Thump Estimates, Buoyed By Robust iPhone Sales, Record Services Revenue

By Shanthi Rexaline

May 4, 4:55 PM

Apple, Inc. (NASDAQ:AAPL) reported second-quarter results that exceeded expectations Thursday, in line with the positive earnings trend seen…

AAPL

What’s Going On With Mullen Automotive Stock?

By Erica Kollmann

September 5, 12:20 PM

Mullen Automotive, Inc. (NASDAQ: MULN) shares are trading higher Tuesday. The stock has lost more than 50% of its value over the last month. What To Know:

MULN

Cardiff Oncology Shares Pop After Lead Asset In KRAS-Mutated Colorectal Cancer

By Vandana Singh

September 12, 9:15 AM

Clinical-stage biotech Cardiff Oncology Inc (NASDAQ:CRDF) announced new preclinical and clinical data from its lead program in KRAS-mutated metastatic colorectal carcinoma (mCRC)…

CRDF

Apellis Pharmaceuticals Q4 EPS $(1.50) Beats $(1.57) Estimate

By Bill Haddad

February 21, 6:00 PM

Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.57) by 4.46 percent. This is a 6.83 percent increase over losses of $(1.61) per share

APLS

BTIG Downgrades T2 Biosystems to Neutral

Related Posts

Apple Q2 Earnings Thump Estimates, Buoyed By Robust iPhone Sales, Record Services Revenue

What’s Going On With Mullen Automotive Stock?

Cardiff Oncology Shares Pop After Lead Asset In KRAS-Mutated Colorectal Cancer

Apellis Pharmaceuticals Q4 EPS $(1.50) Beats $(1.57) Estimate